RESOLUTION 
Expressing support for continued investment to complete the 
development of an HIV vaccine. 
Whereas HIV affects the entire globe and exists in a variety 
of subtypes; 
Whereas, in 2019, the estimated number of new HIV infec-
tions in adults and adolescents was approximately 
34,800, and the overall rate of new HIV infections was 
12.6 cases per 100,000 people in the United States; 
Whereas, at the end of 2019, the estimated HIV prevalence 
rate for persons 13 years of age and older in the United 
States was 431.0 per 100,000 people; 
Whereas, as of 2019, Black Americans have a rate of HIV 
infection that is 8.1 times higher than that of White 
Americans; 
03:13 Dec 02, 2022
HR1506
2 
•HRES 1506 IH 
Whereas, in 2019, there were 6.0 cases of HIV per 100,000 
people that progressed from HIV to AIDS in the United 
States; 
Whereas, at the end of 2019, the AIDS prevalence rate 
among adults and adolescents in the United States was 
estimated at 192.3 per 100,000 people; 
Whereas, each year, more than 12,000 people with AIDS die 
in the United States; 
Whereas the people diagnosed with HIV in 2018 in the 
United States will pay a combined estimated lifetime 
total of $13,700,000,000 in direct medical expenses; 
Whereas it is estimated that patients on antiretroviral ther-
apy with access to discounted medication have lifetime 
medical costs averaging $420,285, which rises to an aver-
age of $1,079,999 for patients without such access, based 
on an estimated life expectancy of 37.31 years after diag-
nosis; 
Whereas, in fiscal year 2022 alone, United States Federal do-
mestic discretionary funding for HIV/AIDS programs to-
taled $7,425,800,000; 
Whereas the United States has contributed a total of 
$23,170,000,000 since 2002 to the Global Fund to Fight 
AIDS, Tuberculosis and Malaria, a multilateral effort 
supported by a number of countries and nongovernmental 
organizations; 
Whereas alternatives for preventing HIV transmission, for-
merly limited to abstinence, education, circumcision, and 
condoms, now include HIV prevention medicines such as 
preexposure prophylaxis (PrEP) and postexposure pro-
phylaxis (PEP); 
03:13 Dec 02, 2022
HR1506
3 
•HRES 1506 IH 
Whereas 3 HIV vaccines (BG505 MD39.3 mRNA, BG505 
MD39.3 gp151 mRNA, and BG505 MD39.3 gp151 
CD4KO mRNA) are currently in National Institutes of 
Health-funded phase 1 trials; 
Whereas President Biden has pledged to develop and imple-
ment a comprehensive national HIV/AIDS strategy that 
will include a focus on reducing HIV incidence; and 
Whereas continued government investment toward a viable 
HIV vaccine has the potential to improve public health 
in the United States: Now, therefore, be it 
Resolved, That the House of Representatives strongly 
1
encourages domestic efforts in the public and private sec-
2
tors to invest in and complete the development of a vaccine 
3
for HIV. 
4
Æ 
03:13 Dec 02, 2022
HR1506
